MZE782 Phase 1 Trial in Healthy Volunteers to Provide Proof of Mechanism Data for Phenylketonuria (PKU) and Chronic Kidney Disease (CKD) Expected in Q3 2025
Related Questions
What are the projected revenue implications of the MZE782 Phase 1 trial results for PKU and CKD?
How will the Q3 2025 proof‑of‑mechanism data release affect the stock’s valuation in the short term?
What is the expected cost and cash burn associated with the Phase 1 trial and subsequent development stages?
Does Maze Therapeutics have sufficient liquidity to fund the next phases of MZE782 without additional financing?
Are there any partnership or licensing opportunities that could be unlocked by positive Phase 1 data?
What market size and pricing assumptions are being used for PKU and CKD indications?
How might the Phase 1 results impact analyst consensus estimates and target price for MZE?
What risks exist if the proof‑of‑mechanism data does not meet expectations or is delayed?
How does the anticipated timeline for MZE782 compare to similar programs from competitors?
What are the potential regulatory pathways and milestones for MZE782 after proof of mechanism is demonstrated?